HTR2 T Cells / Baylor College of Medicine - LARVOL DELTA

TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=27 | Recruiting | Sponsor: Baylor College of Medicine | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Baylor College of Medicine | Trial completion date: Sep 2034 ➔ Jan 2044 | Trial primary completion date: Sep 2028 ➔ Jan 2029

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Baylor College of Medicine | Trial completion date: Jun 2034 ➔ Sep 2034 | Trial primary completion date: Jun 2028 ➔ Sep 2028

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor

TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Baylor College of Medicine | Trial completion date: Jan 2034 ➔ Jun 2034 | Trial primary completion date: Jan 2028 ➔ Jun 2028

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor

TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Baylor College of Medicine | Trial completion date: Aug 2033 ➔ Jan 2034 | Initiation date: Jun 2024 ➔ Jan 2025 | Trial primary completion date: Aug 2027 ➔ Jan 2028

CAR T-Cell Therapy • Metastases • Trial completion date • Trial initiation date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor

TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Baylor College of Medicine | Initiation date: Mar 2024 ➔ Jun 2024

CAR T-Cell Therapy • Metastases • Trial initiation date • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor